XERS News and Press, Xeris Pharmaceuticals Inc. From 06/16/23

2023-06-16 20:41:21 ET Summary Xeris Biopharma Holdings Inc is a growing healthcare company with strong revenue growth and a solid balance sheet, making it an attractive investment option. XERS has a range of successful products, such as Glucagon and Gvoke, and is aggressively sec...

2023-06-15 17:38:38 ET Gainers: Adobe  ( ADBE ) +5% . Arcturus Therapeutics  ( ARCT ) +5% . Xeris Biopharma Holdings ( XERS ) +4% . Castle Biosciences ( CSTL ) +4% . Enovix Corporation ( ENVX ) +4% . Losers: Mil...

Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients’ lives by developing and commercializing innovative products across a range of therapies, today announced that members of its senior management will participate in a f...

2023-05-09 14:24:02 ET Xeris Biopharma Holdings, Inc. (XERS) Q1 2023 Earnings Conference Call May 09, 2023, 08:30 AM ET Company Participants Allison Wey - Senior Vice President, Investor Relations, and Corporate Communications Paul Edick - Chairman and Chief Executiv...

2023-05-09 07:03:17 ET Xeris Pharmaceuticals press release ( NASDAQ: XERS ): Q1 GAAP EPS of -$0.12 beats by $0.05 . Revenue of $33.2M (+51.5% Y/Y) beats by $2.43M . FY2023 Outlook : Total revenue of $135M-$165M vs. consensus of $146.9M; cash utilization fro...

Achieved first quarter total revenue of $33.2M representing 50% growth compared to Q1 2022 Ended Q1 2023 with $95.1M in cash, cash equivalents, and short-term investments Affirms 2023 guidance: total revenue of $135M-$165M; cash utilization from operating activities of $57M-$77M; ...

2023-05-08 12:35:57 ET Xeris Pharmaceuticals ( NASDAQ: XERS ) is scheduled to announce Q1 earnings results on Tuesday, May 9th, before market open. The consensus EPS Estimate is -$0.15 (+40.0% Y/Y) and the consensus Revenue Estimate is $30.77M (+40.4% Y/Y). Over the la...

Conference call and webcast at 8:30am ET Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients’ lives by developing and commercializing innovative products across a range of therapies, today announced that the C...

2023-04-18 07:42:03 ET Xeris Biopharma ( NASDAQ: XERS ) said that the U.S. Patent and Trademark Office issued a patent covering its XeriSol formulations. The Patent Number 11,590,205 is titled 'Methods for producing stable therapeutic glucagon formulations in aprotic pola...

Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients’ lives by developing and commercializing innovative products across a range of therapies, today announced that the U.S. Patent and Trademark Office has issued US Paten...